Design, Synthesis, Molecular Docking, and Biological Evaluation of Isatin-Based Fused Heterocycles As Epidermal Growth Factor Receptor Inhibitors.
Erlotinib Hydrochloride
/ pharmacology
Structure-Activity Relationship
Molecular Docking Simulation
Isatin
/ pharmacology
Cell Proliferation
Cell Line, Tumor
Protein Kinase Inhibitors
/ pharmacology
Drug Screening Assays, Antitumor
ErbB Receptors
/ metabolism
Antineoplastic Agents
/ chemistry
Molecular Structure
Drug Design
EGFR
anticancer
docking
quinazoline
quinoxaline
Journal
Assay and drug development technologies
ISSN: 1557-8127
Titre abrégé: Assay Drug Dev Technol
Pays: United States
ID NLM: 101151468
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
medline:
19
7
2023
pubmed:
13
7
2023
entrez:
13
7
2023
Statut:
ppublish
Résumé
A series of isatin-based fused heterocycles were designed, synthesized, and evaluated for anticancer activity against four cancer cell lines: MCF-7, MDA-MB-231, A549, and HL-60. Among them, Q
Identifiants
pubmed: 37439798
doi: 10.1089/adt.2022.120
doi:
Substances chimiques
Erlotinib Hydrochloride
DA87705X9K
Isatin
82X95S7M06
Protein Kinase Inhibitors
0
ErbB Receptors
EC 2.7.10.1
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM